Posted 27th March 2020 by Joshua Sewell
This article is republished with kind permission from BioVox.
Augustine Therapeutics is one of VIB’s latest spinoffs, developing a first-in-class drug for Charcot-Marie-Tooth disease. The company recently announced a seed-funding round of €4.2 million, led by V-Bio Ventures. We spoke to several of the key persons in Augustine about how the startup is tackling the “Valley of Death”: the no-man’s-land between academia and industry where many potential therapies often fail.